Silo Pharma hires Eric Weisblum as CEO with $350K salary, extends Columbia research pact

Silo Pharma, Inc.

Eric Weisblum appointed CEO; base salary $350K/yr, signing bonus $100K, annual bonus up to $350K.
Severance includes 24 months base salary, COBRA coverage, and prorated bonus on termination without cause or change in control.
Columbia University agreement extended; option to license SPC-14 (Alzheimer's) and SPC-15 (stress-induced anxiety).
CFO Daniel Ryweck salary increased to $60K/yr per amendment dated October 12, 2022.

item 1.01 item 5.02 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Eric Weisblum

Chief Executive Officer

SILO · Silo Pharma, Inc.

Effective: 2022-10-12
Filed: October 18, 2022, 7:59 PM ET

On October 12, 2022, the Company entered into an employment agreement with Eric Weisblum (the “Weisblum Employment Agreement”)

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.7

Eric Weisblum was appointed as Chief Executive Officer at Silo Pharma, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On October 12, 2022, the Company entered into an employment agreement with Eric Weisblum (the “Weisblum Employment Agreement”)

View on SEC.gov

Silo Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-064735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.